BioGaia (OM:BIOG B) Could Be 28% Undervalued As Colus Launch Tests Growth Story

What the BioGaia Colus launch means for BioGaia stock

BioGaia (OM:BIOG B) has launched BioGaia Colus, a clinically tested probiotic capsule targeting the lower gastrointestinal tract, starting in the UK with a planned expansion into other selected markets.

Recent trading shows mixed momentum for BioGaia. The 1-day share price return of 1.76% and 7-day gain of 2.23% contrast with a 30-day share price decline of 5.09%, while the 5-year total shareholder return of 47.77% points to stronger longer run performance.

The BioGaia Colus launch lands just after this short-term pullback. Investors may see the new product as a potential growth driver that could help explain why year-to-date share price return is still up 4.76% and 3-year total shareholder return sits at 26.86%.

Scan beyond BioGaia and this product launch by comparing it with hand picked gut health and healthcare peers in the list of solid balance sheet and fundamentals (198 results).

BioGaia now trades at a double digit discount to both intrinsic estimates and analyst targets after a recent pullback. Is that caution mispriced, or a fair reflection of Colus execution risk?

Most Popular Narrative: 28% Undervalued

On the latest numbers, BioGaia shares at SEK110 are being compared with a widely followed fair value estimate of SEK152.50, which points to a clear valuation gap built on specific growth and margin assumptions rather than vague optimism.

Accelerated investment in marketing and clinical research, though temporarily pressuring EBIT and net margins, supports competitive positioning as consumers increasingly prioritize natural and science-backed probiotics. This suggests current margin compression is transitory and that margins are likely to expand as scale is achieved and investments normalize.

See why 16 investors see BioGaia as 28% undervalued.

Result: Fair Value of SEK152.50 (UNDERVALUED)

Still, high operating costs, weaker cash generation, and heavy reliance on pediatric products could quickly challenge the BioGaia rerating story.

Find out about the key risks to this BioGaia narrative.

Another View on BioGaia valuation

The fair value story for BioGaia does not end with cash flow models. On a P/E of 32x, the stock trades well above the European Biotechs average of 18.2x, yet slightly below its own fair ratio of 33.5x. That combination points to higher expectations and raises a simple question: is the premium multiple a cushion or a risk if growth assumptions change?

To see how this valuation gap looks when you line up BioGaia against peers, take a closer look at the detailed multiple breakdown in the See what the numbers say about this price — find out in our valuation breakdown..

Next Steps

Plenty in this BioGaia story points in different directions, so do not wait for a consensus to form before checking the numbers yourself and weighing both sides. To see the balance of concerns and potential upside in one place, review the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond BioGaia?

If you stop with BioGaia, you may miss opportunities that fit your style even better. Take a few minutes to scan wider using the Simply Wall Street Screener.

• Target resilient balance sheets by filtering for companies with strong finances using the list of solid balance sheet and fundamentals (198 results).
• Hunt for mispriced opportunities by reviewing the 180 high quality undervalued stocks and see which businesses the numbers point to as potentially overlooked.
• Build a steadier income stream by focusing on companies in the 158 dividend fortresses that pair higher yields with stability checks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com